The landmark CANTOS trial further demonstrated that targeted anti-inflammatory therapy with canakinumab significantly reduced major adverse cardiovascular events (MACE) in post-myocardial infarction patients with persistent inflammation, as evidenced by elevated high-sensitivity CRP levels (>2 mg/L) (38). This evidence concerns the gene CRP and myocardial infarction.